Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
Mayo Clinic
ClinicalTrials.gov Identifier:
NCT00645866
First received: March 27, 2008
Last updated: May 13, 2011
Last verified: May 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2006
  Primary Completion Date: March 2006 (Final data collection date for primary outcome measure)